Currently, a small-molecule inhibitor of MSI2, Ro 08-2750, is undergoing a pre-clinical study [47] and has shown high in vivo efficacy against chronic lymphocytic leukemia (CLL) [48], with more similar drugs are being tested [49, 50]. This evidence concerns the gene MSI2 and B-cell chronic lymphocytic leukemia.